A multicenter, non-randomized, pilot study (NCT03143270) is testing the safety and feasibility of the drug eluting bead transarterial chemoembolization (deb-TACE) in combination with nivolumab (anti-PD-1 mAb) in subjects with advanced HCC [76]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.